about the author

Lia DeGroot

ldegroot@endpointsnews.com

author articles

BIO, PhRMA press FDA for con­crete de­tails on new IT strat­e­gy

Last year
Pharma
FDA+

Phath­om notch­es FDA ap­proval for Vo­quez­na to treat ero­sive GERD

Last year
Pharma
FDA+

House Re­pub­li­cans threat­en FDA with sub­poe­na over al­leged in­ad­e­quate lab safe­ty over­sight

Last year
Pharma
FDA+

No­var­tis scores sixth Cosen­tyx ap­proval from FDA, this time to treat hidradeni­tis sup­pu­ra­ti­va

Last year
Pharma
FDA+

Q&A: PureTech CEO Daphne Zo­har talks biotech in­ter­ests on Capi­tol Hill

Last year
People
FDA+

Biden signs sweep­ing ex­ec­u­tive or­der on AI, with changes com­ing for FDA and health­care

Last year
AI
FDA+

Sen­ate De­moc­rats urge Biden ad­min­is­tra­tion to re­quire in­sur­ers to cov­er OTC birth con­trol

Last year
Pharma
FDA+

CMS to kick off Medicare drug price ne­go­ti­a­tion lis­ten­ing ses­sions next week

Last year
Pharma
FDA+

Study: On­col­o­gists who take phar­ma mon­ey are more like­ly to pro­vide low-val­ue treat­ments

Last year
Pharma
FDA+

Law­mak­ers push for faster, con­di­tion­al FDA ap­proval path­way for rare dis­ease drugs

Last year
Pharma
FDA+

NIH nom­i­nee Mon­i­ca Bertag­nol­li clears Sen­ate pan­el with bi­par­ti­san sup­port de­spite Sanders’ drug pric­ing qualms

Last year
People
Pharma

Sanders goes af­ter NIH for grant­i­ng ex­clu­sive patent for po­ten­tial can­cer ther­a­py

Last year
Pharma
FDA+

Un­ap­proved us­es of ap­proved drugs: FDA lays out phar­ma con­sid­er­a­tions for in­form­ing providers

Last year
Pharma
FDA+

House Re­pub­li­cans threat­en sub­poe­na over de­tails of NIH mpox re­search

Last year
FDA+

RWD and RWE are not the same: FDA lead­ers dis­pel com­mon mis­con­cep­tions in new pa­per

Last year
Pharma
FDA+

PTC to sell roy­al­ties on block­buster SMA drug Evrys­di for up to $1.5B

Last year
Deals
Pharma

NIH di­rec­tor nom­i­nee Bertag­nol­li skirts drug pric­ing ques­tions at con­fir­ma­tion hear­ing

Last year
People
Pharma

US vs. Eu­rope: New re­search pa­per com­pares drug re­view times across bor­ders

Last year
Pharma
FDA+

Bris­tol My­ers scores an­oth­er Op­di­vo ap­proval, as Mer­ck con­verts AA to full ap­proval for Keytru­da in MCC

Last year
Pharma
FDA+

HHS se­lects in­tranasal vac­cine can­di­dates for Project NextGen, doles out $500M in funds

Last year
Financing

BIO, PhRMA, oth­ers seek tweaks to FDA draft guid­ance on di­ver­si­ty in post­mar­ket­ing stud­ies

Last year
Pharma
FDA+

Qual­i­ty con­sid­er­a­tions for top­i­cal eye treat­ments: FDA pub­lish­es new draft guid­ance

Last year
Pharma
FDA+

GSK looks to au­tho­rized gener­ic ver­sion of asth­ma treat­ment as Med­ic­aid re­bate caps lift next year

Last year
Pharma
FDA+

CMS post­pones na­tion­al cov­er­age de­ter­mi­na­tion for PrEP, says de­ci­sion is 'forth­com­ing'

Last year
Pharma
FDA+
First page Previous page 567891011 Next page Last page
A service from the Financial Times